European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

General practitioners’ ranking of evidence‐based prescribing quality indicators: a comparative study with a prescription database

“…This showed an increased rate of prescribing of statins when compared with the result from previous studies on the use of statins in Ireland [23]. However, these rates are lower than desired, bearing in mind the clinical evidence of the benefits of statins and aspirin therapy among highrisk groups [6,12,16]. According to current guidelines [6,12], patients with Type 2 diabetes, cerebrovascular disease and peripheral artery disease merit the same degree of attention to treatment of plasma lipids as patients with coronary artery disease, and all such atrisk populations should be eligible to receive statins unless contraindicated.…”

“…Eleven prescribing quality indicators based on various aspects of quality (cost, safety, optimum prescribing in clinical conditions) were identified from the literature [6][7][8][9][10][11][12][13][14][15][16][17][18]. All indicators were presented as good indicators, e.g.…”

“…However, these rates are lower than desired, bearing in mind the clinical evidence of the benefits of statins and aspirin therapy among highrisk groups [6,12,16]. According to current guidelines [6,12], patients with Type 2 diabetes, cerebrovascular disease and peripheral artery disease merit the same degree of attention to treatment of plasma lipids as patients with coronary artery disease, and all such atrisk populations should be eligible to receive statins unless contraindicated. In addition, a meta-analysis conducted by the Antiplatelet Trialists' Collaboration has demonstrated that aspirin reduced the risk of ischaemic vascular events as a secondary prevention strategy in numerous high-risk groups, including patients with diabetes [24].…”

Low HDL‐cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan‐European survey

“…Diabetes amplifies the adverse prognosis associated with cardiovascular risk factors and increases the risk of adverse cardiovascular outcomes by about two-to fourfold compared with subjects without diabetes [1]. Guidelines for the management of cardiovascular risk in the USA [1,2] and in Europe [3,4] recognize diabetes as a coronary heart disease (CHD) risk equivalent. As the number of people with diabetes rises, so will the absolute burden of cardiovascular disease [5].…”

Variation of patients’ views on Type 2 diabetes management over time

“…It is important in this context to underline that it is not our aim to rank the categories or to imply that one group is better than another. This is especially true of Disease Managers and the Compliant: the Compliant also had good glycaemic control according to guidelines of diabetes treatment [15][16][17]. This latter group of people, however, did not perceive an independent role in their treatment, and therefore still needed more support from the health-care system, implying greater service use.…”